Sobrevida en el tratamiento del colangiocarcinoma intrahepatico con quimioembolizacion transarterial: revision sistematica

Castro Núñez, Ana Maria

Sobrevida en el tratamiento del colangiocarcinoma intrahepatico con quimioembolizacion transarterial: revision sistematica

dc.contributor.advisor	Porras, Alexandra
dc.contributor.advisor	Rico, Alejandro
dc.contributor.author	Castro Núñez, Ana Maria
dc.date.accessioned	2024-08-21T16:33:10Z
dc.date.available	2024-08-21T16:33:10Z
dc.date.issued	2024-05
dc.description.abstract	Los colangiocarcinomas son neoplasias malignas del tracto biliar que, según su ubicación anatómica, se clasifican en: distal, perihiliar e intrahepático. Actualmente existen investigaciones sobre tratamiento para hepatocarcinomas, pero los estudios varían en sus diseños y sugerencias. El objetivo de la revisión sistemática es evaluar las implicaciones de la quimioembolizacion transarterial en colangiocarcinoma intrahepatico, considerando sus implicaciones en calidad de vida, supervivencia y riesgo de mortalidad.
dc.description.abstractenglish	Cholangiocarcinomas are malignant neoplasms of the biliary tract that, depending on their anatomical location, are classified as: distal, perihilar and intrahepatic. There is currently research on treatment for hepatocellular carcinoma, but the studies vary in their designs and suggestions. The objective of the systematic review is to evaluate the implications of transarterial quemoembolization inintrahepatic cholangiocarcinoma, considering its implications on quality of life, survival and risk of mortality.
dc.description.degreelevel	Maestría	spa
dc.description.degreename	Magíster en Epidemiología	spa
dc.format.mimetype	application/pdf
dc.identifier.instname	instname:Universidad El Bosque	spa
dc.identifier.reponame	reponame:Repositorio Institucional Universidad El Bosque	spa
dc.identifier.repourl	repourl:https://repositorio.unbosque.edu.co
dc.identifier.uri	https://hdl.handle.net/20.500.12495/12893
dc.language.iso	es
dc.publisher.faculty	Facultad de Medicina	spa
dc.publisher.grantor	Universidad El Bosque	spa
dc.publisher.program	Maestría en Epidemiología	spa
dc.relation.references	Adeva J, Sangro B, Salati M, Edeline J, La Casta A, Bittoni A, et al. Medical treatment for cholangiocarcinoma. Liver International, 2019; 39(1): 123-142.
dc.relation.references	Benson A, D’Angelica M, Abbott D, Abrams T, Alberts S, Anaya D, et al. Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. J Natl Compr Canc Netw. 2019; 17(4):302–10.
dc.relation.references	Boehm L, Jayakrishnan T, Miura J, Zacharias A, Johnston F, Turaga K, et al. Comparative effectiveness of hepatic artery-based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of surgical oncology, 2015; 111(2): 213-220.
dc.relation.references	Boehm L, Jayakrishnan T, Miura J, Zacharias A, Johnston F, Turaga K, et al. Comparative effectiveness of hepatic artery-based therapies for unresectable intrahepatic cholangiocarcinoma. Journal of surgical oncology, 2015; 111(2): 213-220.
dc.relation.references	Burt A, Alves V, Bedossa P, Clouston A, Guido M, Hübscher S, et al. Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2018; 73(3): 369-385.
dc.relation.references	Cloyd J, Mizuno T, Kawaguchi Y, Lillemoe H, Karagkounis G, Omichi K, et al. Comprehensive Complication Index Validates Improved Outcomes Over Time Despite Increased Complexity in 3707 Consecutive Hepatectomy. Ann Surg, 2020; 271(1): 724–731.
dc.relation.references	Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly J, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (Prodige 12-accord 18-Unicancer GI): A randomized phase III study. J. Clin. Oncol, 2019; 37(1): 658–667.
dc.relation.references	Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly J, et al. Gemcitabine and oxaliplatin chemotherapy or surveillance in resected biliary tract cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): a randomized phase III study. Journal of Clinical Oncology, 2019; 37(8): 658-667.
dc.relation.references	Edge S, Compton C. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Annals of surgical oncology, 2010; 17(6): 1471-1474.
dc.relation.references	Florio A, Ferlay J, Znaor A, Ruggieri D, Alvarez C, Laversanne M, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer, 2020; 126(11): 2666-2678.
dc.relation.references	Friman S. Cholangiocarcinoma—current treatment options. Scandinavian Journal of Surgery, 2011; 100(1): 30-34.
dc.relation.references	Ge Y, Jeong S, Luo G, Ren Y, Zhang B, Zhang Y, et al. Transarterial chemoembolization versus percutaneous microwave coagulation therapy for recurrent unresectable intrahepatic cholangiocarcinoma: Development of a prognostic nomogram. Hepatobiliary & Pancreatic Diseases International, 2020; 19(2): 138-146.
dc.relation.references	Higaki T, Aramaki O, Moriguchi M, Nakayama H, Midorikawa Y, Takayama T. Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma. BioScience Trends, 2018; 12(1): 73-78.
dc.relation.references	Hyder O, Marsh J, Salem R, Petre E, Kalva S, Liapi E, et al. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Annals of surgical oncology, 2013; 20(1): 3779-3786.
dc.relation.references	Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley R, Wang K, et al. Biliary cancer: Utility of next-generation sequencing for clinical management. Cancer, 2016; 122(1): 3838–3847.
dc.relation.references	Jeong Y, Shin H, Lee S, Cheun H, Ju J W, Kim J, et al. Prevalence of Clonorchis sinensis infection among residents along 5 major rivers in the Republic of Korea. The Korean Journal of Parasitology, 2016; 54(2): 215.
dc.relation.references	Kiefer M, Albert M, McNally M, Robertson M, Sun W, Fraker D, et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2‐center study. Cancer, 2011; 117(7): 1498-1505.
dc.relation.references	Kitphati R, Watanawong O, Wongsaroj T, Nithikathkul C. National Program of Opisthorchiasis in Thailand; Situation and Policy Strategy. International Journal of Geoinformatics, 2021; 17(2): 61-68.
dc.relation.references	Li J, Wang Q, Lei Z, Wu D, Si A, Wang K, et al. Adjuvant transarterial chemoembolization following liver resection for intrahepatic cholangiocarcinoma based on survival risk stratification. The oncologist, 2015; 20(6): 640-647.
dc.relation.references	Luo J, Zheng J, Shi C, Fang J, Peng Z, Huang J, et al. Drug-eluting beads transarterial chemoembolization by CalliSpheres is effective and well tolerated in treating intrahepatic cholangiocarcinoma patients: A preliminary result from CTILC study. Medicine,2020; 99(12): e19276.
dc.relation.references	Massarweh N, El-Serag H. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer control, 2017; 24(3): 1073274817729245.
dc.relation.references	Moris D, Palta M, Kim C, Allen P, Morse M, Lidsky M. Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians. CA: a cancer journal for clinicians, 2023; 73(2): 198-222.
dc.relation.references	Our E, Verster A. Access to hepatitis C care for people who inject drugs and people in prisons. The Lancet Gastroenterology & Hepatology, 2019; 4(9): 662-663.
dc.relation.references	Peng Z, Cao G, Hou Q, Li L, Ying S, Sun J, et al. The comprehensive analysis of efficacy and safety of CalliSpheres® drug-eluting beads transarterial chemoembolization in 367 liver cancer patients: A multiple-center, cohort study. Oncology research, 2020; 28(3): 249271.
dc.relation.references	Primrose J, Fox R, Palmer D, Malik H, Prasad R, Mirza D, et al. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): A randomised, controlled, multicentre, phase 3 study. Lancet Oncol, 2019; 20(1): 663–673.
dc.relation.references	Rizvi S, Khan S, Hallemeier C, Kelley R, Gores G. Cholangiocarcinoma—evolving concepts and therapeutic strategies. Nature reviews Clinical oncology, 2018; 15(2): 95-111.
dc.relation.references	Roayaie S, Guarrera J, Michele Q, Thung S, Emre S, Fishbein T, et al. Aggressive surgical treatment of intrahepatic cholangiocarcinoma: predictors of outcomes. Journal of the American College of Surgeons, 1998; 187(4): 365-372.
dc.relation.references	Shen F, Xie ZH, Xia Y, Wu M. Progress on surgical treatment of intrahepatic cholangiocarcinoma. Zhonghua Wai Ke Za Zhi, 2019; 57(4):241–6.
dc.relation.references	Shen W, Zhong W, Liu Q, Sui C, Huang Y, Yang J. Adjuvant transcatheter arterial chemoembolization for intrahepatic cholangiocarcinoma after curative surgery: retrospective control study. World journal of surgery, 2011; 35(1): 2083-2091.
dc.relation.references	Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. New England Journal of Medicine, 2010; 362(14): 1273-1281.
dc.relation.references	Wright G, Perkins S, Jones H, Zureikat A, Marsh J, Holtzman M, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a comparison of surgical resection with intra-arterial therapies. Annals of Surgical Oncology,2018; 25(1): 83-90.
dc.relation.references	Wu L, Tsilimigras D, Paredes A, Mehta R, Hyer J, Merath K, et al. Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival. World journal of surgery, 2019; 43 (1): 1777-1787.
dc.relation.references	Zhang X, Chen Q, Kimbrough C, Beal E, Lv Y, Chakedis J, et al. Lymphadenectomy for Intrahepatic Cholangiocarcinoma: Has Nodal Evaluation Been Increasingly Adopted by Surgeons over Time? A National Database Analysis. J. Gastrointest. Surg, 2018; 22(1): 668–675.
dc.rights	Atribución-NoComercial-CompartirIgual 4.0 Internacional
dc.rights.accessrights	info:eu-repo/semantics/openAccess
dc.rights.accessrights	info:eu-repo/semantics/openAccess
dc.rights.local	Acceso abierto	spa
dc.rights.uri	http://creativecommons.org/licenses/by-nc-sa/4.0/
dc.subject	Quimioembolización transarterial
dc.subject	Colangiocarcinoma intrahepatico
dc.subject	Sobrevida
dc.subject.keywords	Transarterial chemoembolization
dc.subject.keywords	Intrahepatic cholanciocarcinoma
dc.subject.keywords	Survival
dc.subject.nlm	WA 105
dc.title	Sobrevida en el tratamiento del colangiocarcinoma intrahepatico con quimioembolizacion transarterial: revision sistematica
dc.title.translated	Survival in the treatment of intrahepatic cholangiocarcinoma with transarterial chemoembolization: systematic review
dc.type.coar	https://purl.org/coar/resource_type/c_bdcc
dc.type.coarversion	https://purl.org/coar/version/c_ab4af688f83e57aa
dc.type.driver	info:eu-repo/semantics/masterThesis
dc.type.hasversion	info:eu-repo/semantics/acceptedVersion
dc.type.local	Tesis/Trabajo de grado - Monografía - Maestría	spa